Share on StockTwits

Research analysts at Bank of America hoisted their price objective on shares of Shire PLC (LON:SHP) from GBX 3,859 ($65.67) to GBX 4,500 ($76.58) in a research note issued on Wednesday. The firm currently has a “buy” rating on the stock. Bank of America’s target price indicates a potential upside of 2.18% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Shore Capital reiterated a “buy” rating on shares of Shire PLC in a research note on Wednesday. Separately, analysts at Barclays reiterated an “overweight” rating on shares of Shire PLC in a research note on Wednesday. They now have a GBX 3,900 ($66.37) price target on the stock. Finally, analysts at Credit Suisse raised their price target on shares of Shire PLC from GBX 3,400 ($57.86) to GBX 4,200 ($71.48) in a research note on Monday. They now have a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Shire PLC presently has a consensus rating of “Buy” and a consensus target price of GBX 3,096.81 ($52.70).

Shire PLC (LON:SHP) opened at 4489.00 on Wednesday. Shire PLC has a 52-week low of GBX 1989.00 and a 52-week high of GBX 4491.00. The stock has a 50-day moving average of GBX 3526.33 and a 200-day moving average of GBX 3166.. The company’s market cap is £26.229 billion.

Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.